MAPT and Alzheimer disease: In addition to the elevated VDAC1 levels observed in AD cases, studies have demonstrated that VDAC1 directly interacts with Aβ and phosphorylated tau, impairing the opening and closing of mitochondrial pores, ultimately leading to mitochondrial dysfunction [41].